Non-occupational post-exposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  McDougal, Sarah J ^a   Alexander, Jeremiah ^a,b   Dhanireddy, Shireesha ^a   Harrington, Robert D ^a   Stekler, Joanne D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Department of Epidemiology University of Washington ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE CONTROL; ELECTRONIC MEDICAL RECORD; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS; POST EXPOSURE PROPHYLAXIS; PRESCRIPTION; PUBLIC HEALTH; RETROSPECTIVE STUDY; SEROPREVALENCE; UNITED STATES; VIRUS LOAD; VIRUS TRANSMISSION; AGED; EVALUATION STUDY; HIV INFECTIONS; MIDDLE AGED; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; RETROSPECTIVE STUDIES; RISK FACTORS; WASHINGTON; YOUNG ADULT;

EID: 84919353125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105030     Document Type: Article

References (37)

1. (CDC) CfDCaP (1995) Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood-France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep 44: 929-933.
2. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, et al. (1997) A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 337: 1485-1490. (Pubitemid 27495773)
3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, et al. (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331: 1173-1180. (Pubitemid 24331334)
4. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, et al. (1996) Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 335: 1621-1629. (Pubitemid 26392726)
5. Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, et al. (2005) Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 54: 1-20.
6. Kahn JO, Martin JN, Roland ME, Bamberger JD, Chesney M, et al. (2001) Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 183: 707-714. (Pubitemid 32171744)
7. Kunches LM, Meehan TM, Boutwell RC, McGuire JF (2001) Survey of nonoccupational HIV postexposure prophylaxis in hospital emergency departments. J Acquir Immune Defic Syndr 26: 263-265. (Pubitemid 32246556)
8. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, et al. (2004) Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 18: 2065-2073. (Pubitemid 39463360)
9. Grob PM, Cao Y, Muchmore E, Ho DD, Norris S, et al. (1997) Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nat Med 3: 665-670. (Pubitemid 27264977)
10. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, et al. (1998) Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 72: 4265-4273. (Pubitemid 28188732)
11. Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, et al. (2000) Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 74: 9771-9775.
12. Tissot F, Erard V, Dang T, Cavassini M (2010) Nonoccupational HIV post-exposure prophylaxis: a 10-year retrospective analysis. HIV Med 11: 584-592.
13. McCarty EJ, Quah S, Maw R, Dinsmore WW, Emerson CR (2011) Post-exposure prophylaxis following sexual exposure to HIV: a seven-year retrospective analysis in a regional centre. Int J STD AIDS 22: 407-408.
14. Poynten IM, Smith DE, Cooper DA, Kaldor JM, Grulich AE (2007) The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Med 8: 374-381. (Pubitemid 47163269)
15. Balaji AB, Bowles KE, Le BC, Paz-Bailey G, Oster AM (2013) High HIV incidence and prevalence and associated factors among young MSM, 2008. AIDS 27: 269-278.
16. Baggaley RF, White RG, Boily MC (2010) HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 39: 1048-1063.
17. Varghese B, Maher JE, Peterman TA, Branson BM, Steketee RW (2002) Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis 29: 38-43. (Pubitemid 34074430)
18. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, et al. (2004) Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 164: 46-54. (Pubitemid 38067388)
19. Herida M, Larsen C, Lot F, Laporte A, Desenclos JC, et al. (2006) Cost-effectiveness of HIV post-exposure prophylaxis in France. AIDS 20: 1753-1761. (Pubitemid 44299367)
20. (CDC) CfDCaP (2013) HIV infection among heterosexuals at increased risk-United States, 2010. MMWR Morb Mortal Wkly Rep 62: 183-188.
21. (CDC) CfDCaP (2010) Prevalence and awareness of HIV infection among men who have sex with men - 21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep 24: 1201-1207.
22. HIV/AIDS Epidemiology Unit PHSKCatIDAU, Washington State Department of Health (2012) HIV/AIDS Epidemiology Report, Second Half 2012. 81.
23. Buskin S (2008) HIV/AIDS Epidemiology Report, Second Half 2008. Seattle, Washington: Public Health - Seattle & King County, Washington State Department of Health. 37 p.
24. HIV/AIDS Epidemiology Unit PHSKC, Washington State Department of Health (2010) HIV/AIDS Epidemiology Report, Second Half 2010.
25. Mehta SA, Silvera R, Bernstein K, Holzman RS, Aberg JA, et al. (2011) Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sex Transm Infect 87: 344-348.
26. de Silva S, Miller RF, Walsh J (2006) Lack of awareness of HIV post-exposure prophylaxis among HIV-infected and uninfected men attending an inner London clinic. Int J STD AIDS 17: 629-630. (Pubitemid 44338268)
27. Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, et al. (2008) Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 47: 241-247. (Pubitemid 351172193)
28. Armishaw J, Hoy JF, Watson KM, Wright EJ, Price BG, et al. (2011) Non-occupational post-exposure prophylaxis in Victoria, Australia: responding to high rates of re-presentation and low rates of follow-up. Int J STD AIDS 22: 714-718.
29. Correll P, Smith D, Grulich A (2000) Post-exposure prophylaxis for non-occupational exposure to HIV: Experience in New South Wales one year after the introduction of the guidelines. N S W Public Health Bull 11: 113-118.
30. Lunding S, Katzenstein TL, Kronborg G, Lindberg JA, Jensen J, et al. (2010) The Danish PEP registry: experience with the use of postexposure prophylaxis (PEP) following sexual exposure to HIV from 1998 to 2006. Sex Transm Dis 37: 49-52.
31. Sonder GJ, van den Hoek A, Regez RM, Brinkman K, Prins JM, et al. (2007) Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004. Sex Transm Dis 34: 288-293. (Pubitemid 46707481)
32. Available: http://www.hivinfosource.org/hivis/clinicaltrials/ testingproject.html HIV InfoSource.NYC Medical Center. Accessed 2013 January 10.
33. Rey D, Bendiane MK, Bouhnik AD, Almeda J, Moatti JP, et al. (2008) Physicians' and patients' adherence to antiretroviral prophylaxis after sexual exposure to HIV: results from South-Eastern France. AIDS Care 20: 537-541.
34. Laporte A, Jourdan N, Bouvet E, Lamontagne F, Pillonel J, et al. (2002) Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes. AIDS 16: 397-405. (Pubitemid 34165371)
35. Golden MR, Stekler J, Hughes JP, Wood RW (2008) HIV serosorting in men who have sex with men: is it safe? J Acquir Immune Defic Syndr 49: 212-218.
36. Golden MR, Dombrowski JC, Kerani RP, Stekler JD (2012) Failure of serosorting to protect African American men who have sex with men from HIV infection. Sex Transm Dis 39: 659-664.
37. Chacko L, Ford N, Sbaiti M, Siddiqui R (2012) Adherence to HIV post-exposure prophylaxis in victims of sexual assault: a systematic review and metaanalysis. Sex Transm Infect 88: 335-341.